Company intelligence / Profile preview

Stimgenics

Bloomington, Illinois, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Stimgenics developed a proprietary spinal cord stimulation waveform called Differential Target Multiplexed Spinal Cord Stimulation (DTM SCS), which modulates both neurons and glial cells to treat chronic pain. Preclinical studies showed statistically significant reversal of pain behaviors compared to traditional low or high frequency stimulation. The company received multiple awards for its research prior to being acquired by Medtronic in January 2020. DTM SCS became part of Medtronic’s Intellis platform for chronic pain management.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Implantable Medical Devices

Partnerships

None reported prior to acquisition; now part of Medtronic’s partnerships.

Beyond the preview

Go deeper on Stimgenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stimgenics.

Explore the full profile